The phase III MonarcHER trial analyzed the efficacy of abemaciclib plus trastuzumab, with or without fulvestrant, versus standard of care (CT plus trastuzumab) in HR-positive/HER2-positive advanced BC. The gene discussed is ERBB2; the disease is breast cancer.